January 26th, 2023 (Earnings Report) Dear Reader,
HealthTechMovers.com just identified several healthtech stocks that are expected to release earnings starting today, January 26th. If you are interested in any of these companies, we encourage you to do your own research and due diligence before pursuing any investments. Keep in mind, the actual earnings date and time may change, so if you’re interested in any of these companies you will need to pay close attention to their announcements.
23andMe Holding
Symbol: ME
Recent Price: $2.6
Average Analyst Price Target: $6.50 (150.00%)
Last Year's EPS: -$0.21
Consensus EPS Forecast: -$0.19
Expected Earnings Date: Feb 07 2023
Recent Analyst Action: Gaurav Goparaju, analyst at Berenberg Bank, reiterates coverage on 23andMe Holding (ME) in the Healthcare sector with a Buy rating and a price target of $ 7 (1 month ago).
Click for complete article >>Recent Analyst Action: Salim Syed, analyst at Mizuho Securities, reiterates coverage on Atara Biotherapeutics (ATRA) in the Healthcare sector with a Buy rating and a price target of $ 31 (22 hours ago).
Click for complete article >>Recent Analyst Action: Vijay Kumar, analyst at Evercore ISI, reiterates coverage on Azenta (AZTA) in the Healthcare sector with a Hold rating and a price target of $ 62 (1 month ago).
Click for complete article >>Recent Analyst Action: Jason Bednar, analyst at Piper Sandler, reiterates coverage on Envista Holdings (NVST) in the Healthcare sector with a Buy rating and a price target of $ 46 (22 hours ago).
Click for complete article >>Recent Analyst Action: Matthew Harrison, analyst at Morgan Stanley, reiterates coverage on Innoviva (INVA) in the Healthcare sector with a Sell rating and a price target of $ 13 (1 week ago).
Click for complete article >>Recent Analyst Action: Matt Nirenberg, analyst at Oppenheimer, reiterates coverage on Invacare (IVC) in the Healthcare sector with a Buy rating and a price target of $ 2 (2 months ago).
Click for complete article >>Recent Analyst Action: Andrew Fein, analyst at H.C. Wainwright, reiterates coverage on Kamada (KMDA) in the Healthcare sector with a Buy rating and a price target of $ 11 (2 months ago).
Click for complete article >>
To Your Financial Future,
The Editor, HealthTechMovers.com